Provenge extends life for up to 4 years, especially when your PSA levels are lower at the beginning of treatment with Provenge.
Provenge is an immunotherapy treatment that is specifically used for metastatic, castrate resistant prostate cancer.
A real world study called the PROCEED Registry, evaluated the safety and the survival of nearly 2,000 men who used Provenge and found that men treated with Provenge when their PSA level was lower had a median overall survival of nearly 4 years or 47.7 months.
Men who start Provenge when their PSA level is lower live longer than men who start Provenge when their PSA level is higher.
The FDA approved Provenge for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.
And after treatment with Provenge, other options such as hormone therapy, chemotherapy and radiotherapy as well can also often be used.
The side effects of a Provenge infusion include nausea, fatigue, vomiting, fever, chills or rigor, respiratory events, dyspnea, hypoxia, bronchospasm, hypotension, syncope, hypertension and tachycardia.